India, Oct. 19 -- Shares of Summit Therapeutics Inc. (SMMT) are rising 7 percent in Monday morning trading after the company announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma.
The company's shares are currently trading at $15.69 on the Nasdaq, gaining 7.25 percent in the latest session. The stock opened at $14.90 and touched an intraday high of $15.68. Over the past 12 months, the shares have traded between $12.07 and $29.23.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permi...